Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib
Frontiers in Oncology · 04.06.2026 · 16
DOI: 10.3389/fonc.2026.1709014 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 04.06.2026. Verfasst von Junqi Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Academy of Traditional Chinese Medicine, Affiliated Hospital, Changsha, China. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Selpercatinib is a highly selective RET inhibitor with potent activity in RET-driven malignancies. Zoledronic acid is a standard bone-modifying agent for bone metastases, but its potential to induce hyperprogressive disease (HPD) is unclear. We present a 59-year-old woman with neuroendocrine carcinoma of unknown primary carrying a RET p.V804M mutation and widespread metastases. She achieved partial remission for 6 months with Selpercatinib plus denosumab. After switching to zoledronic acid, she developed HPD within 1 month, with severe bone pain, sharply elevated NSE, and radiological progression. Her condition deteriorated rapidly, and she died 8 months post-diagnosis. A strong temporal correlation suggests a potential triggering role of zoledronic acid, but causality is unproven. Tumor aggressiveness and acquired resistance to Selpercatinib are plausible alternative explanations. Mechanisms involving FPPS inhibition, Ras dysregulation, and γδ T-cell activation remain speculative. This hypothesis-generating case indicates that switching bone-modifying agents during RET inhibitor therapy requires close monitoring. Further studies are needed to confirm the safety and mechanisms underlying HPD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hunan Academy of Traditional Chinese Medicine, Affiliated Hospital, Changsha, China.
Zitieren
APA
Liu, J., & He, F. (2026). Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1709014
Vancouver
Liu J, He F. Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1709014
BibTeX
@article{Liu2026,
author = {Liu, Junqi and He, FengJiao},
title = {Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1709014}
}
EUVIMED